Expert view: Where are you seeing changes in the flow cytometry market?
We have entered a new era of drug discovery where the use of advanced cell models such as multi-cellular co-cultures, stem cells and CRISPR-based screens can lead to the next generation of therapeutics.
As an example, in the field of oncology, the focus has shifted to a novel class of biologics and cell therapies that modulate immune cell function. This change in therapeutic approach and model complexity requires tools that assess multiple cell parameters to better understand the cellular mechanisms or synergistic effects of combinatorial drug treatments earlier in the discovery process. Furthermore, severe constraints on essential primary cells drive the desire to miniaturise assays and compress analysis workflows.